A Response to: A Letter to the Editor Regarding 'Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Older Adults: Systematic Literature Review and Meta-Analysis Using the GRADE Framework'

Infect Dis Ther. 2024 Oct;13(10):2195-2202. doi: 10.1007/s40121-024-01020-2. Epub 2024 Aug 24.

¹ Moderna, Inc., 200 Technology Square, Cambridge, MA, 02139, USA. [email protected].
² Moderna, Inc., 200 Technology Square, Cambridge, MA, 02139, USA.
³ ICON plc, Stockholm, Sweden.

No abstract available

Keywords: BNT162b2; COVID-19; Effectiveness; Older adults; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; mRNA vaccine; mRNA-1273.

Publication types